Immunotech Biopharm's 2024 Loss Narrows

MT Newswires Live
04-01

Immunotech Biopharm's (HKG:6978) loss attributable to owners in 2024 narrowed year on year to 186.9 million yuan or 0.36 per share from 334.8 million yuan or 0.65 yuan per share, according to a Hong Kong Stock Exchange disclosure on Monday.

The biopharmaceutical company's other income surged 220% to 33.8 million yuan from 10.5 million yuan in the previous year.

No dividend was recommended for the period.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

no data

没有相关数据

如果下载按钮点击无跳转,请点击右上角菜单选择 “在浏览器打开”